April 17, 1980New England Journal of Medicine
Total Suppression of Ventricular Arrhythmias by Encainide
Why the study?
Does oral encainide suppress ventricular arrhythmias in patients with stable high-frequency ventricular arrhythmias?
Population
11 patients with stable high-frequency ventricular arrhythmias
Comparison
Oral encainide vs Placebo (in a crossover design)
Design
RCT, placebo-controlled
Follow-up
6 to 12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports encainide for stable ventricular arrhythmia suppression; extends RCT dose-response data despite PR/QRS prolongation.
Structured PICO
Does oral encainide suppress ventricular arrhythmias in patients with stable high-frequency ventricular arrhythmias?
P
Population
11 patients with stable high-frequency ventricular arrhythmias
I
Intervention
Oral encainide (range of doses, administered every 6 to 12 hours)
C
Comparator
Placebo (in a crossover design)
O
Outcome
Total suppression of ventricular arrhythmiasurrogate
Oral encainide effectively suppressed high-frequency ventricular arrhythmias in a small cohort, though it caused significant PR and QRS prolongation.
Cite This Study
Roden et al. (1980) studied this question.